跳至主要内容
临床试验/NCT06195137
NCT06195137已完成不适用

Efficacy of Caffeine vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment

Lu Jiang1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2021年12月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
130
试验地点
1
主要终点
Visual Analogue Scale (VAS)

研究概览

简要总结

The aim of this study was to evaluate the efficacy of caffeine and alpha-lipoic acid in the treatment of burning mouth syndrome by symptom assessment with visual analogue scale.

详细描述

The etiology of BMS is multifactorial, involving a complex interplay of neuropathic, psychological, neuroendocrine, and immunological factors. Neurologically, BMS has been categorized into three subtypes: peripheral small fiber neuropathy, subclinical trigeminal neuropathy, and inhibitory dopaminergic deficiency. Neuroimaging and peripheral nerve studies have further implicated altered brain activation patterns and increased expression of specific receptors like TRPV1 and P2X3 in the pathogenesis of BMS. Hormonal imbalances, particularly in estrogen levels, have also been suggested to contribute to contribute to the condition.

Caffeine, a xanthine alkaloid chemically known as 1,3,7-trimethylxanthine, is recognized for its diverse biological functions. As a central nervous system stimulant, its primary mechanism involves antagonizing adenosine receptors, thereby enhancing the release of neurotransmitters such as dopamine and norepinephrine, which are known to play roles in analgesic pathways. Caffeine is also noted for its neuroprotective properties and is theorized to reduce the risk of neurodegenerative diseases. It affects the central processing of pain and is involved in regulating circadian rhythms and sleep-wake cycles. Additionally, caffeine has mild anti-inflammatory properties. Its stimulatory effects may also improve mood and cognitive function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults over 18 years of age
  • Diagnosis of BMS according to the 3rd edition of the International Classification of Headache Disorders (ICHD-3)
  • Daily intraoral burning or dysaesthesia lasting for more than 2 hours for over 3 months
  • Normal oral mucosa and sensory testing
  • Condition not better accounted for by another ICHD-3 diagnosis

排除标准

  • Secondary BMS due to local or systemic disorders
  • Prior treatment for BMS
  • Psychiatric or progressive neurological disorders
  • Systemic disorders potentially associated with oral disease
  • Long-term history of smoking, drinking, or medication use
  • Consumption of caffeinated products
  • Poor oral hygiene
  • Abnormal blood test results (including blood count, glucose, serum iron, ferritin and transferrin, folic acid, or vitamin B12 levels)
  • Incomplete medical records
  • Unwillingness to participate

研究组 & 干预措施

Caffeine group

Experimental

Burning mouth syndrome (BMS) patients in Caffeine group were provided with BMS disease explanation and psychological counseling. Then they were told to drink instant coffee containing 120-150 mg of the active ingredient caffeine (2 bags of Nescafe Black Coffee, 1.8g each) at a certain point in time from 8:00 to 12:00 every day, for 2 consecutive weeks.

干预措施: Caffeine (Dietary Supplement)

Alpha Lipoic Acid (ALA) group

Active Comparator

Burning mouth syndrome (BMS) patients in the ALA group were provided with BMS disease explanation and psychological counseling. Then they took α-lipoic acid (ALA) 3 times a day, after meals, 200 mg each time, for 2 consecutive weeks.

干预措施: Alpha Lipoic Acid (Drug)

结局指标

主要结局

Visual Analogue Scale (VAS)

时间窗: Baseline and 2 weeks after intervention or observation

During the interview or telephone follow-up with the patient, ask the patient to fill in the VAS rating scale.

次要结局

未报告次要终点

研究者

发起方
Lu Jiang
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Lu Jiang

Clinical Professor

Sichuan University

研究点 (1)

Loading locations...

相似试验